Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2013;4(6):144.
doi: 10.1186/scrt355.

A new hope for patients suffering from multiple myeloma

Jinhua Yu, Yao Li
Comment

A new hope for patients suffering from multiple myeloma

Jinhua Yu et al. Stem Cell Res Ther. 2013.

Abstract

Multiple myeloma is a common hematological malignancy that leads to the occurrence of bone lesions. The combination of traditional cytotoxic and novel agents is usually taken to treat multiple myeloma-related bone diseases. However, the curative effect is not very satisfactory. Stem cell-based therapy has been recently introduced and investigated, which represents a new frontier in the treatment of multiple myeloma. In a recent interesting study, Dr Atsuta and colleagues provide a new insight into the effects of mesenchymal stem cells on multiple myeloma via Fas/Fas ligand pathway, which rekindles the fire of hope for those patients suffering from multiple myeloma.

PubMed Disclaimer

Comment on

References

    1. Atsuta I, Liu S, Miura Y, Akiyama K, Chen C, An Y, Shi S, Chen FM. Mesenchymal stem cells inhibit multiple myeloma cells via the Fas/Fas ligand pathway. Stem Cell Res Ther. 2013;4:111. doi: 10.1186/scrt322. - DOI - PMC - PubMed
    1. Mazar J, Thomas M, Bezrukov L, Chanturia A, Pekkurnaz G, Yin S, Kuznetsov SA, Robey PG, Zimmerberg J. Cytotoxicity mediated by the Fas ligand (FasL)-activated apoptotic pathway in stem cells. J Biol Chem. 2009;4:22022–22028. doi: 10.1074/jbc.M109.032235. - DOI - PMC - PubMed
    1. Roccaro AM, Sacco A, Maiso P, Azab AK, Tai YT, Reagan M, Azab F, Flores LM, Campigotto F, Weller E, Anderson KC, Scadden DT, Ghobrial IM. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest. 2013;4:1542–1555. doi: 10.1172/JCI66517. - DOI - PMC - PubMed
    1. Ciavarella S, Caselli A, Savonarola A, Tamma AV, Tucci M, Silvestris F. Cytotherapies in multiple myeloma: a complementary approach to current treatments? Expert Opin Biol Ther. 2013;4:S23–S34. doi: 10.1517/14712598.2013.796357. - DOI - PubMed
    1. Fu J, Wang P, Zhang X, Ju S, Li J, Li B, Yu S, Zhang J. Myeloma cells inhibit osteogenic differentiation of mesenchymal stem cells and kill osteoblasts via TRAIL-induced apoptosis. Arch Med Sci. 2010;4:496–504. - PMC - PubMed